secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nexentis Technologies Inc. (NXTS)
CIK:        0001789192
Form:       8-K
Filed at:   2025-09-25T23:59:59+00:00
Accession:  0001493152-25-014952
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

N2OFF shareholders approve acquisition of MitoCareX Bio; closing targeted by early Oct 2025
--------------------------------------------------------------------------------

- Stockholders voted 11.7M for, 197K against to approve the MitoCareX acquisition; reverse split and warrant share proposals also passed.
- N2OFF will acquire MitoCareX from SciSparc (SPRC) and others for $700K plus shares equal to 40% of fully diluted stock.
- Sellers get 30% of financing proceeds (capped at $1.6M) for 5 years and milestone issuances up to 25% of common stock.
- N2OFF commits an initial $1M cash investment to support MitoCareX operations for two years post-closing.
- A 1-for-35 reverse stock split was already effected on Sept 22; the approved split range (1:2 to 1:150) allows further action within one year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789192/000149315225014952/0001493152-25-014952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789192/000149315225014952/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-014952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer